Compare Charles River Laboratories Intl. Inc (CRL) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Kingsoft Cloud Holdings Limited — how do they compare? Charles River Laboratories Intl. Inc trades at $231.94 (market cap $11.14B), while Kingsoft Cloud Holdings Limited trades at $10.11 (market cap $2.93B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.8× Kingsoft Cloud Holdings Limited's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Kingsoft Cloud Holdings Limited nearer its low. Which is the better fit depends on your goals.
| CRL | KC | |
|---|---|---|
Market Cap | $11.14B | $2.93B |
Sector | Health | Technology |
52-Week High | $233.60 | $18.21 |
52-Week Low | $145.57 | $8.58 |
Enterprise Value | $14.00B | $3.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Kingsoft Cloud (KC) trades at $10.39, down 4.77% today, with a bullish technical signal and strong analyst support (70% buy ratings). Recent quarters show consistent earnings beats, though the company remains unprofitable with a -9.39% net margin. Revenue growth is robust, driven by AI cloud demand, while cash flow from operations improved to $3.80B in 2025. Technical indicators suggest bullish momentum with support near $10 and resistance at $11.
The stock presents a growth opportunity amid China's AI expansion, but profitability challenges and high valuation multiples pose risks. Analyst consensus points to 25.4% upside potential, though execution on margin improvement is critical for sustained gains. Macroeconomic and regulatory factors in China remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
